Immunology

LOCAL IMMUNE CHECKPOINT INHIBITION

Nov 13, 2017

| Reference: 

B75080

  • Trispecific molecules (LiCADs, local inhibitor checkpoint antibody derivatives) enable local (tumor) immune checkpoint inhibition, which avoids systemic side effects
  • LiCADs comprise binding sites with specificity for a tumor cell, for an effector cell and for a checkpoint molecule
  • Checkpoint binding is restricted and concentrated to tumor cells avoiding undesired toxicity to healthy cells and accordingly systemic side effects
Read more

NF-κB-ACTIVATED DENDRITIC CELLS

Nov 13, 2017

| Reference: 

B71259

  • Novel DC-vaccination strategy for cancer immunotherapy that has very little adverse effects and overcomes the limitations of DC based immunotherapy approaches
  • DCs activation is mediated by triggering their NF-κB-pathway via mRNA transfection
  • Activated DCs show increased IL-12 production, have the capacity to repetitively stimulate and expand antigen-specific CTLs, lead to strong expansion of effector T cells (memory T cells) and are much more stable compared to other DC vaccination products
Read more

PROTEIN PURIFICATION/IMMOBILIZATION THROUGH NEG-PEPS

Sep 16, 2017

| Reference: 

B76080

  • NegPeps (magnetic particle binding peptides) are novel peptides with the potential to replace the common affinity tags based protein purification/immobilization 
  • NegPeps bind to magnetic nanoparticles in a reversible and controlled manner
  • No specific surface functionalization necessary 
Read more

LALISTAT: TREATING MYCOBACTERIAL DISEASES

Sep 16, 2017

| Reference: 

B75235

  • Novel approach for treating tuberculosis (TB) by the Lipase inhibitor Lalistat
  • Lalistat specifically abrogates the intracellular growth of mycobacterium tuberculosis
  • The use of Lalistat in combination with known antimycobacterial might offer an urgently needed opportunity to improve and shorten TB therapy
Read more

SMALL MOLECULE HDAC6 INHIBITORS

Sep 16, 2017

| Reference: 

B73271

  • ‍HDAC6 is a promising target for the treatment of chronic immune and inflammatory disorders such as rheumatoid arthritis (RA)
  • Marbostat are new small molecule inhibitors of HDAC6 with superior characteristics: in comparison to the established HDAC6 inhibitor Tubastatin A, the new inhibitors are more potent and specific, and most importantly they highly and selectively inhibit the enzyme activity of HDAC6 without destroying the protein.
  • Provision of a viable alternative to first line NSAIDs (non-steroidal anti-inflammatory drugs) in the treatment of RA
Read more

IMPROVING STABILITY AND SECRETION OF ANTIBODIES

Sep 16, 2017

| Reference: 

B73076

  • Improvement of the biophysical properties of antibodies and enhancement of antibody secretion by imitating the stabilizing structural elements of shark antibodies
  • CL domain is modified by a conservative exchange of amino acids at two positions
  • Compared to the wild type CL, the melting point of the modified CL domain is almost 10°C higher and its stability against urea-induced denaturation is also markedly increased 
Read more

SMALL MOLECULE INHIBITORS OF CD40-TRAF6 INTERACTIONS

Sep 16, 2017

| Reference: 

B72031

  • New selective inhibitors for treatment of chronic inflammatory diseases, such as atherosclerosis, obesity and multiple sclerosis
  • Inhibitors selectively block CD40-TRAF6 interactions
  • The selective blockage of the CD40-TRAF6 interactions strongly reduces inflammation, whereas unwanted immune-suppressive side effects are reduced
Read more

METHOD FOR IDENTIFICATION OF TARGET ANTIGENS OF T-CELLS

Sep 16, 2017

| Reference: 

B70007

  • ‍Identify peptide antigens of any CD8 restricted TCR (CD4 ongoing)
  • Affinity independent and extremely sensitive method
  • Focused on autoimmune diseases and psoriasis but also applicable to tumor immunology
Read more